SS-31 — Mitochondria-targeted peptide (Szeto-Schiller peptide)
Selectively concentrates in inner mitochondrial membrane, binds cardiolipin to stabilize cristae structure, optimizes electron transport chain efficiency, reduces reactive oxygen species (ROS) production, and prevents cytochrome c release (anti-apoptotic).
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Mitochondria-targeted peptide (Szeto-Schiller peptide)
Mechanism of Action
Selectively concentrates in inner mitochondrial membrane, binds cardiolipin to stabilize cristae structure, optimizes electron transport chain efficiency, reduces reactive oxygen species (ROS) production, and prevents cytochrome c release (anti-apoptotic).
Regulatory Status
Not FDA approved; FDA rejected NDA 2023; ongoing trials
Evidence Level
Moderate — Phase 2/3 trials in Barth syndrome and heart failure